On December 20, 2021 Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, reported that senior management will participate in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022 (Press release, Chemomab, DEC 20, 2021, View Source [SID1234597445]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event details are below:

Chemomab_Logo
View File Download File
Chemomab_Logo
LifeSci Partners 11th Annual Corporate Access Event

Date: January 5-7, 2022
Format: 1-on-1 virtual meetings with senior management
Registration: LifeSci Partners Corporate Access Event 2022

HC Wainwright BioConnect 2022 Virtual Healthcare Conference

Date: Webcast available on demand at 7:00am ET Jan.10 through Jan.13, 2022
Format: Corporate overview webcast
Registration: View Source
Replay: Available on Chemomab website starting Jan.14, 2022 at investors.chemomab.com/events